- Home
- QFIN vs NUVL Comparison
QFIN vs NUVL Comparison
Compare QFIN & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QFIN
- NUVL
- Stock Information
- Founded
- QFIN 2016
- NUVL 2017
- Country
- QFIN China
- NUVL United States
- Employees
- QFIN N/A
- NUVL N/A
- Industry
- QFIN Finance: Consumer Services
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- QFIN Finance
- NUVL Health Care
- Exchange
- QFIN Nasdaq
- NUVL Nasdaq
- Market Cap
- QFIN 5.9B
- NUVL 6.7B
- IPO Year
- QFIN 2018
- NUVL 2021
- Fundamental
- Price
- QFIN $38.49
- NUVL $86.68
- Analyst Decision
- QFIN Strong Buy
- NUVL Strong Buy
- Analyst Count
- QFIN 1
- NUVL 10
- Target Price
- QFIN $37.50
- NUVL $112.60
- AVG Volume (30 Days)
- QFIN 1.6M
- NUVL 350.8K
- Earning Date
- QFIN 11-19-2024
- NUVL 11-12-2024
- Dividend Yield
- QFIN 2.97%
- NUVL N/A
- EPS Growth
- QFIN 42.14
- NUVL N/A
- EPS
- QFIN 4.99
- NUVL N/A
- Revenue
- QFIN $2,449,056,522.00
- NUVL N/A
- Revenue This Year
- QFIN $6.22
- NUVL N/A
- Revenue Next Year
- QFIN $4.03
- NUVL N/A
- P/E Ratio
- QFIN $7.68
- NUVL N/A
- Revenue Growth
- QFIN 9.41
- NUVL N/A
- 52 Week Low
- QFIN $13.71
- NUVL $61.80
- 52 Week High
- QFIN $40.31
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- QFIN 65.01
- NUVL 36.14
- Support Level
- QFIN $37.55
- NUVL $84.64
- Resistance Level
- QFIN $40.31
- NUVL $89.31
- Average True Range (ATR)
- QFIN 1.34
- NUVL 2.82
- MACD
- QFIN 0.16
- NUVL -0.72
- Stochastic Oscillator
- QFIN 89.69
- NUVL 20.93
About QFIN Qifu Technology Inc.
Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.